Investment Thesis
Aligos Therapeutics is a pre-revenue stage biopharmaceutical company with severe cash burn and minimal revenue generation, indicating the pipeline has not yet achieved meaningful commercialization. The company is burning cash at an unsustainable rate ($82.6M negative free cash flow annually) while maintaining only $18.3M in cash reserves, creating critical liquidity concerns within 3-6 months. Without evidence of clinical success or revenue inflection, the company faces existential risk despite reasonable balance sheet leverage.
ALGS Strengths
- Strong current ratio of 3.90x provides near-term liquidity cushion
- Zero long-term debt reduces financial leverage and restructuring risk
- Stockholders equity of $53.5M provides some asset base for potential reorganization
- 4 Form 4 insider filings in last 90 days suggest active management engagement
ALGS Risks
- Negative operating cash flow of $82.5M with only $18.3M cash on hand implies runway of ~2-3 months without additional capital raises
- Net margin of -1106.7% and operating margin of -4024.9% demonstrate business model failure at current stage
- Revenue of $2.2M flat YoY indicates no commercial traction despite being a public company
- Sustained negative free cash flow of $82.6M annually is economically unsustainable without continuous dilutive financing
- Pre-revenue biotech with massive losses suggests pipeline failures or delayed market adoption
Key Metrics to Watch
- Monthly cash burn rate and projected cash runway length
- Clinical trial progression and regulatory approval milestones for pipeline candidates
- Quarterly revenue growth and gross margin achievement from any commercialized products
- Capital raise announcements and dilution percentage from future equity issuances
ALGS Financial Metrics
ALGS Profitability Ratios
ALGS Balance Sheet & Liquidity
ALGS 5-Year Financial Trend
5-Year Trend Summary: Aligos Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-20.94 indicates the company is currently unprofitable.
ALGS Growth Metrics (YoY)
ALGS Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $741.0K | -$4.3M | $-0.44 |
| Q2 2025 | $965.0K | $5.1M | $0.81 |
| Q1 2025 | $311.0K | -$34.9M | $-2.11 |
| Q3 2024 | $1.1M | -$18.0M | $-3.07 |
| Q2 2024 | $1.1M | $5.1M | $0.03 |
| Q1 2024 | $140.0K | -$23.0M | $-0.22 |
| Q3 2023 | N/A | -$18.0M | $-0.41 |
| Q2 2023 | N/A | -$18.8M | $-0.43 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ALGS Capital Allocation
ALGS SEC Filings
Access official SEC EDGAR filings for Aligos Therapeutics, Inc. (CIK: 0001799448)